Feasibility investigation of allogeneic endometrial regenerative cells

doi:10.1186/1479-5876-7-15

Journal of Translational Medicine

Volume 7

Viewing options:

Abstract
Full text
PDF (273KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Zhong Z
Patel AN
Ichim TE
Riordan NH
Wang H
Min WP
Woods EJ
Reid M
Mansilla E
Marin GH
Drago H
Murphy MP
Minev B

on PubMed

Zhong Z
Patel AN
Ichim TE
Riordan NH
Wang H
Min WP
Woods EJ
Reid M
Mansilla E
Marin GH
Drago H
Murphy MP
Minev B
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research

Feasibility investigation of allogeneic endometrial regenerative cells

Zhaohui Zhong¹ , Amit N Patel² , Thomas E Ichim³ , Neil H Riordan³ , Hao Wang⁴ , Wei-Ping Min⁴ , Erik J Woods⁵ , Michael Reid⁶ , Eduardo Mansilla⁷ , Gustavo H Marin⁷ , Hugo Drago⁷ , Michael P Murphy⁸ and Boris Minev⁹^,10

¹The Second Xiangya Hospital, Central South University, Changsha, PR China

²Department of Cardiothoracic Surgery, University of Utah, Salt Lake City, USA

³Medistem Inc, San Diego, USA

⁴Department of Surgery, University of Western Ontario, Canada

⁵General Biotechnology LLC, Indiana, USA

⁶Body in Motion Consulting, Kitchener, Canada

⁷Burns Hospital, Buenos Aires City, Argentina

⁸Division of Vascular Surgery, Indiana University School of Medicine, Indiana, USA

⁹Moores Cancer Center, University of California, San Diego

¹⁰Division of Neurosurgery, University of California San Diego, San Diego, USA

author email corresponding author email

Journal of Translational Medicine 2009, 7:15doi:10.1186/1479-5876-7-15


Published:	20 February 2009

Abstract

Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like stem cells having pluripotent differentiation activity and ability to induce neoangiogenesis. In vitro and animal studies suggest ERC are immune privileged and in certain situations actively suppress ongoing immune responses. In this paper we describe the production of clinical grade ERC and initial safety experiences in 4 patients with multiple sclerosis treated intravenously and intrathecally. The case with the longest follow up, of more than one year, revealed no immunological reactions or treatment associated adverse effects. These preliminary data suggest feasibility of clinical ERC administration and support further studies with this novel stem cell type.